BioLineRx Debt-to-Equity
The Debt-to-Equity Ratio of BioLineRx (BLRX) as of Nov 4, 2026 is 0.56. In the previous year, Debt-to-Equity Ratio was 1.12 — a change of -50.07% (lower).
Get this data via API
Financial Data API
Debt-to-Equity
0.56
YoY
-50.07%
Last updated:
The BioLineRx Debt-to-Equity history
3 Years
10 Years
25 Years
Max
| YEAR | Debt-to-Equity | YoY |
|---|---|---|
| 0.56 | -50.07% | |
| 1.12 | +27.46% | |
| 0.88 | +261.62% | |
| 0.24 | +254.86% | |
| 0.07 | -80.42% | |
| 0.35 | +11.36% | |
| 0.31 | +48.20% | |
| 0.21 | +4,370.46% | |
| 0.00 | -51.72% | |
| 0.01 | +6.69% | |
| 0.01 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioLineRx Stock analysis
Frequently Asked Questions about BioLineRx stock
Debt-to-Equity Ratio of BioLineRx is 0.56 in 2025.
Debt-to-Equity Ratio of BioLineRx changed from 1.12 to 0.56, representing a -50.07% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Debt-to-Equity Ratio BioLineRx since 2006 – with annual values, charts, and detailed analysis.
The Debt-to-Equity ratio measures financial leverage by comparing total debt to shareholders' equity. Higher ratios indicate more debt financing relative to equity.
Debt/Equity = Total Debt / Shareholders' Equity
A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Equity Ratio's BioLineRx with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Leverage — BioLineRx
All Key Metrics — BioLineRx
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth